Aion Therapeutic Inc (AION) AI Stock Analysis

• Market Cap: C$4.84M
• Dividend Yield: N/A
• Average Volume (3M): 55.24K
• Price to Earnings (P/E): ―
• Beta (1Y): -2.85
• Revenue Growth: 563.34%
• EPS Growth: -68.82%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 483,549,260
• 10 Day Avg. Volume: 12,000
• 30 Day Avg. Volume: 55,237
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 31 Underperform
• Price Target: ―

Aion Therapeutic Inc's stock score reflects significant financial weaknesses, including operational losses and high leverage, which weigh heavily on the assessment. The technical analysis indicates a bearish trend, while valuation is challenging due to negative earnings and lack of dividend yield. The company's revenue growth is a positive factor, but substantial improvements are necessary for a more favorable outlook.

Aion Therapeutic Inc Business Overview & Revenue Model

Company Description

Aion Therapeutic Inc (AION) is a biotechnology company focused on the research and development of therapeutic interventions for various health conditions. The company operates in the pharmaceutical and biotechnology sectors, specializing in developing treatments that leverage cannabis, mushrooms, and other natural compounds. Aion Therapeutic aims to create innovative healthcare solutions through its core products and services in the medical and wellness industries.

How the Company Makes Money

Aion Therapeutic Inc generates revenue primarily through the development and commercialization of its proprietary therapeutic products. These products are designed to address a range of health conditions using natural compounds. The company's revenue model includes licensing agreements, product sales, and potential partnerships with larger pharmaceutical firms for distribution and co-development opportunities. Aion's earnings are also influenced by its ongoing research and development efforts, which aim to expand its product pipeline and enhance its market presence in the biotechnology sector. Significant partnerships with research institutions and healthcare providers may also contribute to its revenue streams.

Aion Therapeutic Inc Financial Statement Overview

Summary

Aion Therapeutic Inc faces several financial challenges, including significant operational losses, high leverage, and negative equity, which collectively indicate a precarious financial position. Revenue growth is a positive sign, but substantial improvements in profitability and balance sheet health are needed to strengthen the company's financial standing.

Income Statement

Aion Therapeutic Inc has shown a significant increase in revenue over the past year, moving from no revenue to $1.47 million in TTM (Trailing-Twelve-Months). However, the company continues to face challenges with negative EBIT and EBITDA margins, both of which indicate operational inefficiencies. The net profit margin is also deeply negative at -451.1%, reflecting substantial losses relative to revenue.

Balance Sheet

The company has a negative stockholders' equity, indicating a weak balance sheet with liabilities exceeding assets. Debt levels are high, with a negative equity ratio, showcasing financial instability. The debt-to-equity ratio is not meaningful due to negative equity, but the overall financial leverage is concerning.

Cash Flow

Aion Therapeutic Inc's cash flows are under pressure with negative free cash flow and operating cash flow. There's a significant reliance on financing activities to support operations. The operating cash flow to net income ratio is negative, indicating challenges in converting income into cash.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	367.48K	0.00	0.00	0.00	0.00
Gross Profit	163.12K	-17.30K	-65.29K	―	-111.05K
EBITDA	-6.07M	-89.52K	-3.68M	-7.95M	-240.59K
Net Income	-6.29M	-256.66K	-3.82M	-8.27M	-672.83K
Balance Sheet
Total Assets	702.86K	210.67K	150.14K	1.60M	3.34M
Cash, Cash Equivalents and Short-Term Investments	68.34K	336.00	239.83K	239.83K	612.79K
Total Debt	2.08M	826.47K	744.06K	566.53K	958.91K
Total Liabilities	4.57M	2.94M	2.56M	1.21M	1.20M
Stockholders Equity	-3.87M	-2.73M	-2.41M	397.46K	2.13M
Cash Flow
Free Cash Flow	-845.04K	-41.40K	-2.79M	-3.58M	-756.38K
Operating Cash Flow	-845.04K	-41.40K	-1.35M	-2.13M	-551.75K
Investing Cash Flow	-289.42K	135.19K	-1.38M	-1.38M	-333.19K
Financing Cash Flow	1.12M	163.25K	1.20M	3.00M	-125.00K

Aion Therapeutic Inc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AION, the sentiment is Neutral. The current price of 0.01 is above the 20-day moving average (MA) of <0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.30 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:AION.

Aion Therapeutic Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NEO	72 Outperform	C$700.29M	―	-2.58%	2.35%	0.44%	-434.16%
CURA	65 Neutral	C$3.08B	―	-24.93%	―	-2.64%	1.65%
Sector *	51 Neutral	$7.46B	-0.25	-46.00%	2.25%	22.77%	-2.14%
CYBN	37 Underperform	$1.97M	―	-53.55%	―	―	38.54%
AION	31 Underperform	C$4.84M	―		―	563.34%	-68.82%